Clinical Trial Update: Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis [Phase 2]

View source ↗

Summary

Phase 2 trial of ibrutinib in advanced systemic mastocytosis was terminated with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Systemic Mastocytosis
• Mast Cell Leukemia
• Systemic Mastocytosis

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Jason Robert Gotlib | Conditions: Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2018-09-20